There is provided 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide for various uses, as well as pharmaceutical compositions and devices comprising 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide. There is also provided a method for reducing reducible compounds (such as reduction-activated prodrugs, e.g. tretazicar) by contacting those compounds with ±-hydroxycarbonyl compounds capable of forming cyclic dimers.
